SynthesisEuropean archives of psychiatry and clinical neuroscience2013
Systematic review of the diagnostic utility of SPECT imaging in dementia.
Synthesis in European archives of psychiatry and clinical neuroscience, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 72 citations in OpenAlex.
- Multimodal neuroimaging in dementia and neurodegenerative disorders: complementary roles of clinically available nuclear medicine and MRI in the era of disease-modifying therapies.Japanese journal of radiology · 2026Review
- Relative Brain Perfusion Differences in a Patient With Persistent Cognitive Symptoms: A Case Report.Cureus · 2026Article
- Towards a Multidimensional Model of Neurocognitive Disorders (MOND Model): Integrating Evidence from a Critical Review into a Model for Future Research.Journal of personalized medicine · 2026Review
- Detecting mild cognitive impairment by applying integrated random forest to finger tapping.Medical & biological engineering & computing · 2025Article
- Clinical and Neuropathological Evaluations of the New Brunswick Neurological Syndrome of Unknown Cause.JAMA neurology · 2025Article
- Demystifying the Role of Neuroinflammatory Mediators as Biomarkers for Diagnosis, Prognosis, and Treatment of Alzheimer's Disease: A Review.ACS pharmacology & translational science · 2024Review
- Exploring CNS Involvement in Pain Insensitivity in Hereditary Sensory and Autonomic Neuropathy Type 4: Insights from Tc-99m ECD SPECT Imaging.Tomography (Ann Arbor, Mich.) · 2023Article
- A Pilot Study on Cerebral Blood Flow and Mini-Mental State Examination to Predict Amyloid Deposition in Preclinical Alzheimer's Disease.Psychiatry and clinical psychopharmacology · 2023Article
- Imaging Methods Applicable in the Diagnostics of Alzheimer's Disease, Considering the Involvement of Insulin Resistance.International journal of molecular sciences · 2023Review
- Brain PET Imaging: Frontotemporal Dementia.PET clinics · 2023Review
- The Feasibility of Differentiating Lewy Body Dementia and Alzheimer's Disease by Deep Learning Using ECD SPECT Images.Diagnostics (Basel, Switzerland) · 2021Article
- Inclusion of quasi-vertex views in a brain-dedicated multi-pinhole SPECT system for improved imaging performance.Physics in medicine and biology · 2021Article
- Brain SPECT as an Imaging Biomarker for Evaluating Effects of Novel Treatments in Psychiatry-A Case Series.Frontiers in psychiatry · 2021Article
- Assessment of finger motor function that reflects the severity of cognitive function.Fujita medical journal · 2021Article
- Brain SPECT as a Biomarker of Neurodegeneration in Dementia in the Era of Molecular Imaging: Still a Valid Option?Frontiers in neurology · 2021Review
- Confirmation ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2020Article
- The clinical utilities of multi-pinhole single photon emission computed tomography.Quantitative imaging in medicine and surgery · 2020Review
- Molecular and Imaging Biomarkers in Alzheimer's Disease: A Focus on Recent Insights.Journal of personalized medicine · 2020Review
- DSC Brain Perfusion Using Advanced Deconvolution Models in the Diagnostic Work-up of Dementia and Mild Cognitive Impairment: A Semiquantitative Comparison with HMPAO-SPECT-Brain Perfusion.Journal of clinical medicine · 2020Article
- Machine Learning for Diagnosis of AD and Prediction of MCI Progression From Brain MRI Using Brain Anatomical Analysis Using Diffeomorphic Deformation.Frontiers in neurology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Single-photon emission-computed tomography (SPECT) may potentially contribute to the diagnostic work up of patients with neurodegenerative dementia. This systematic review aims to establish the diagnostic utility of 99mTc-hexamethylpropyleneamine (99mTc-HMPAO) and 99mTc-ethylcysteine dimer SPECT in distinguishing between Alzheimer's disease (AD) and frontotemporal dementia (FTD), AD and vascular dementia (VD), AD and dementia with Lewy bodies (DLB), and AD and normal controls (NC). We searched MEDLINE and Embase databases via OVID for articles from January 1985 to May 2012 and identified additional studies from reviews and references. Of 755 studies, 49 studies met the inclusion and exclusion criteria for this systematic review; AD versus FTD (n=13), AD versus VD (n=18), AD versus DLB (n=5), and AD versus NC (n=18). We compiled relevant data and graded the studies with an internal and external validity criteria checklist. We pooled the studies with a clinical diagnosis and those using 99mTc-HMPAO SPECT in a meta-analysis, calculating the pooled weighted sensitivity, specificity, likelihood ratios, and diagnostic odds ratios using DerSimonian-Laird random-effects model. The pooled weighted sensitivity and specificity of 99mTc-HMPAO-SPECT in distinguishing clinically diagnosed AD from FTD are 79.7 and 79.9%, respectively, AD from VD are 74.5 and 72.4%, AD from DLB are 70.2 and 76.2%, and AD from NC are 76.1 and 85.4%. SPECT does have diagnostic value, particularly in differentiating Alzheimer's disease from frontotemporal dementia and normal controls; however, it should not be used in isolation, rather as an adjunct, and interpreted in the context of clinical information and paraclinical test results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.